Eli Lilly's Says Phase 3 BRUIN CLL-322 Trial of Jaypirca (pirtobrutinib), Plus Venetoclax And Rituximab Met Its Primary Endpoint For Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma

Benzinga Newsdesk www.benzinga.com Positive 85.4%

Neg 0% Neu 0% Pos 85.4%

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm
This trial predominantly enrolled a patient population previously treated with covalent BTK inhibitors, highly relevant to current practice
These results mark the fourth positive Phase 3 study of pirtobrutinib in CLL

Comments

No comments yet. Be the first!

Eli Lilly&#39;s Says Phase 3 BRUIN CLL-322 Trial of Jaypirca (pirtobrutinib), Plus Venetoclax And Rituximab Met Its Primary Endpoint For Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma